CoChat

The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Tumor microenvironments present significant barriers to penetration by antibodies and immunoconjugates. Tumor microenvironments, however, are difficult to study in vitro. Cells cultured as monolayers exhibit less resistance to therapy than those grown in vivo and an alternative research model more representative of the in vivo tumor is more desirable. SS1P is an immunotoxin composed of the Fv portion of a mesothelin-specific antibody fused to a bacterial toxin that is presently undergoing clinical trials in mesothelioma. METHODOLOGY/PRINCIPAL FINDINGS: Here, we examined how the tumor microenvironment affects the penetration and killing activity of SS1P in a new three-dimensional (3D) spheroid model cultured in vitro using the human mesothelioma cell line (NCI-H226) and two primary cell lines isolated from the ascites of malignant mesothelioma patients. Mesothelioma cells grown as monolayers or as spheroids expressed comparable levels of mesothelin; however, spheroids were at least 100 times less affected by SS1P. To understand this disparity in cytotoxicity, we made fluorescence-labeled SS1P molecules and used confocal microscopy to examine the time course of SS1P penetration within spheroids. The penetration was limited after 4 hours. Interestingly, we found a significant increase in the number of tight junctions in the core area of spheroids by electron microscopy. Expression of E-Cadherin, a protein involved in the assembly and sealing of tight junctions and highly expressed in malignant mesothelioma, was found significantly increased in spheroids as compared to monolayers. Moreover, we found that siRNA silencing and antibody inhibition targeting E-Cadherin could enhance SS1P immunotoxin therapy in vitro. CONCLUSION/SIGNIFICANCE: This work is one of the first to investigate immunotoxins in 3D tumor spheroids in vitro. This initial description of an in vitro tumor model may offer a simple and more representative model of in vivo tumors and will allow for further investigations of the microenvironmental effects on drug penetration and tumor cell killing. We believe that the methods developed here may apply to the studies of other tumor-targeting antibodies and immunoconjugates in vitro.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0014640

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Establishment of human mesothelioma spheroids. A. Monolayers and spheroids of human mesothelioma cell line, NCI-H226, and primary mesothelioma lines NCI-M-03 and NCI-M-13. Scale bars, 400 µm (except 200 µm for NCI-M-13 spheroids). B. Immunohistochemical staining of an NCI-H226 spheroid (see Methods ). (a) Mesothelin stains both the membrane and cytoplasm. (b) Calretinin stains both the nuclei and cytoplasm. (c) HBME-1 exhibits a focal membranous staining pattern (arrows). (d) Cytokeratin 5/6 exhibits a focal cytoplasmic staining pattern. (e) WT-1 stains the nuclei. (f) Thrombomodulin exhibits a focal membranous staining pattern close to the rim (arrows).
Figure 1 Establishment of human mesothelioma spheroids. A. Monolayers and spheroids of human mesothelioma cell line, NCI-H226, and primary mesothelioma lines NCI-M-03 and NCI-M-13. Scale bars, 400 µm (except 200 µm for NCI-M-13 spheroids). B. Immunohistochemical staining of an NCI-H226 spheroid (see Methods ). (a) Mesothelin stains both the membrane and cytoplasm. (b) Calretinin stains both the nuclei and cytoplasm. (c) HBME-1 exhibits a focal membranous staining pattern (arrows). (d) Cytokeratin 5/6 exhibits a focal cytoplasmic staining pattern. (e) WT-1 stains the nuclei. (f) Thrombomodulin exhibits a focal membranous staining pattern close to the rim (arrows).CC0 · PubMed Central
Figure 2 Anti-tumor immunotoxin activity on mesothelioma monolayers and spheroids. Cells treated with SS1P and BL22. A. Cell growth inhibition (WST-8 assays) of NCI-H226. IC50 of SS1P for spheroids was >1000 ng/mL. IC50 for monolayers was ∼10 ng/mL. B. Cell viability (CellTiter-Glo Luminescent assays) of NCI-H226. IC50 of SS1P for spheroids was >1000 ng/mL. IC50 for monolayers was ∼5 ng/mL. C. Primary mesothelioma lines NCI-M-03 and NCI-M-13 treated with 100 ng/mL of SS1P. 2D, monolayers; 3D, spheroids. *p<0.01.
Figure 2 Anti-tumor immunotoxin activity on mesothelioma monolayers and spheroids. Cells treated with SS1P and BL22. A. Cell growth inhibition (WST-8 assays) of NCI-H226. IC50 of SS1P for spheroids was >1000 ng/mL. IC50 for monolayers was ∼10 ng/mL. B. Cell viability (CellTiter-Glo Luminescent assays) of NCI-H226. IC50 of SS1P for spheroids was >1000 ng/mL. IC50 for monolayers was ∼5 ng/mL. C. Primary mesothelioma lines NCI-M-03 and NCI-M-13 treated with 100 ng/mL of SS1P. 2D, monolayers; 3D, spheroids. *p<0.01.CC0 · PubMed Central
Figure 3 Mesothelin expression in mesothelioma monolayers and spheroids. NCI-H226 cells incubated with an anti-mesothelin mAb (MN) and detected with goat anti-mouse IgG conjugated with Alexa488 by flow cytometry.
Figure 3 Mesothelin expression in mesothelioma monolayers and spheroids. NCI-H226 cells incubated with an anti-mesothelin mAb (MN) and detected with goat anti-mouse IgG conjugated with Alexa488 by flow cytometry.CC0 · PubMed Central
Figure 4 Penetration of Alexa488-labeled immunotoxin SS1P in tumor spheroids. A. SS1P labeled with Alexa488 (green fluorescence). A cross section close to the middle of an NCI-H226 spheroid evaluated at hours 0, 8 and 16 using confocal microscopy. B. Overlay of bright field and fluorescence images of a spheroid. C. Mean fluorescence intensity of SS1P (see Methods ). Scale bars, 400 µm.
Figure 4 Penetration of Alexa488-labeled immunotoxin SS1P in tumor spheroids. A. SS1P labeled with Alexa488 (green fluorescence). A cross section close to the middle of an NCI-H226 spheroid evaluated at hours 0, 8 and 16 using confocal microscopy. B. Overlay of bright field and fluorescence images of a spheroid. C. Mean fluorescence intensity of SS1P (see Methods ). Scale bars, 400 µm.CC0 · PubMed Central
Figure 5 Electron microscopy of cell contacts in NCI-H226 mesothelioma spheroids. A and B. SEM analysis showing microvilli (arrow). Scale bars, 200 µm (A) and 10 µm (B). C and D. Ultrathin sections (TEM). Presence of intracellular tight junctions (arrow). Scale bar, 0.5 µm. E. Number of cellular junctions in the core and rim areas.
Figure 5 Electron microscopy of cell contacts in NCI-H226 mesothelioma spheroids. A and B. SEM analysis showing microvilli (arrow). Scale bars, 200 µm (A) and 10 µm (B). C and D. Ultrathin sections (TEM). Presence of intracellular tight junctions (arrow). Scale bar, 0.5 µm. E. Number of cellular junctions in the core and rim areas.CC0 · PubMed Central
Figure 6 Expression of cell junction and Bcl-2 signaling proteins in NCI-H226 monolayers and spheroids. A. Protein expression of E-Cadherin, ZO-1, Connexin-32, Mcl-1, Bcl-xL, Bid, Bak, Bax, and β-actin examined by Western blot. B. Molecular mechanisms underlying drug resistance in tumor spheroids.
Figure 6 Expression of cell junction and Bcl-2 signaling proteins in NCI-H226 monolayers and spheroids. A. Protein expression of E-Cadherin, ZO-1, Connexin-32, Mcl-1, Bcl-xL, Bid, Bak, Bax, and β-actin examined by Western blot. B. Molecular mechanisms underlying drug resistance in tumor spheroids.CC0 · PubMed Central
Figure 7 Sensitizing spheroids to immunotoxin therapy in vitro. A. Silencing E-Cadherin expression by siRNA. siE-Cad, E-Cadherin siRNA. 2D: monolayers; 3D: spheroids. B. Silencing E-Cadherin enhanced the anti-tumor activity of SS1P. Cell growth was assessed by incubation with WST-8 with values normalized (%) relative to the growth of the non-silencing siRNA (* p<0.05). C and D. An anti-adhesive mAb targeting E-Cadherin (SHE78-7) enhanced the anti-tumor activity of SS1P when added before the formation of spheroids (Pre) (* p<0.05), but not after (Post). Arrow, lysed cell debris. Scale bars, 400 µm. NS, not significant.
Figure 7 Sensitizing spheroids to immunotoxin therapy in vitro. A. Silencing E-Cadherin expression by siRNA. siE-Cad, E-Cadherin siRNA. 2D: monolayers; 3D: spheroids. B. Silencing E-Cadherin enhanced the anti-tumor activity of SS1P. Cell growth was assessed by incubation with WST-8 with values normalized (%) relative to the growth of the non-silencing siRNA (* p<0.05). C and D. An anti-adhesive mAb targeting E-Cadherin (SHE78-7) enhanced the anti-tumor activity of SS1P when added before the formation of spheroids (Pre) (* p<0.05), but not after (Post). Arrow, lysed cell debris. Scale bars, 400 µm. NS, not significant.CC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 51

Metadata

Authors
Xiang, X., Phung, Y., Feng, M., Nagashima, K., Zhang, J., Broaddus, V. C., Hassan, R., FitzGerald, D., & Ho, M.
Affiliations
  • National Institutes of Health (US)
  • University of California, San Francisco (US)
Corresponding author
Ho, Mitchell
Venue
PLoS ONE
Published
2011-01-31
Volume
6
Issue
1
Pages
e14640
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1994540190
Cited by
51
References
37
Citations by year
2026: 2 · 2025: 3 · 2023: 3 · 2022: 4 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 6 · 2016: 5 · 2015: 4 · 2014: 2 · 2013: 4 · 2012: 5
FWCI
2.13
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, public-domain)
  • Figshare (submittedVersion, cc-by)
Funders
  • U.S. Department of Health and Human Services (HHSN26120080001E)
  • Mesothelioma Applied Research Foundation
  • National Institutes of Health (HHSN26120080001E)
  • National Cancer Institute (HHSN26120080001E)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
malignant mesothelioma, mesothelin, tumor microenvironment, tumor spheroids, drug penetration, tight junctions, E-cadherin, immunoconjugates, siRNA knockdown
MeSH terms
Antibodies, Antibodies, Monoclonal, Immunotoxins, Humans, Kinetics, Mesothelioma, Microscopy, Electron, Tumor Cells, Cultured, Cadherins, Spheroids, Cellular, Cell Culture Techniques, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy. https://app.cochat.ai/papers/10.1371/journal.pone.0014640
The paper
Xiang, X., Phung, Y., Feng, M., Nagashima, K., Zhang, J., Broaddus, V. C., Hassan, R., FitzGerald, D., & Ho, M. (2011). The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy. PLoS ONE. https://doi.org/10.1371/journal.pone.0014640

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.